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Gene therapy consists of the transfer of genetic material
to cells to achieve a therapeutic goal. In the field of
gastroenterology and hepatology gene therapy has
produced considerable expectation as a potential tool
in the management of conditions that lack effective
therapy including non-resectable neoplasms of the liver,
pancreas and gastrointestinal tract, chronic viral
hepatitis unresponsive to interferon therapy, liver
cirrhosis, and inflammatory bowel disease.
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BASIC CONCEPTS
Gene therapy is a new approach to treat human
diseases based on the transfer of genetic material
to the cells. The transferred genetic material is
most commonly a natural gene but it can also be
a chimeric gene or subgenomic molecule. A cell is
said to be transduced when it has incorporated
and expresses a foreign gene.1 To facilitate cell
transduction, the genetic material is packaged
into molecular constructs named vectors, which
can be of viral2 and non-viral nature.3 Viral vectors
are frequently preferred because of their higher
transduction efficiency and can be classified as
long term and short-term expression vectors
(retroviruses, adeno-associated viruses (AAV),
gutless adenoviruses belong to the first category
and first generation adenoviruses to the second).
For a gene to be expressed inside a cell its cod-
ing DNA sequence should be linked to appropri-
ate regulatory DNA sequences. Gene promoters
(and other regulatory elements) may allow trans-
gene expression in every transduced cell (univer-
sal promoters)4 or, alternatively, only in selected
cells containing transcription factors able to
interact specifically with the promoter (as in the
case of tumour specific promoters).5 On the other
hand, promoters may determine a continuous
and fixed expression of the transgene in the
transduced cell or, alternatively, promoter activity
can be sensitive to certain drugs that when given
to the patient can modulate promoter function,
permitting regulatable expression of the
transgene.6 The most challenging issues for a suc-
cessful application of gene therapy to treat
human diseases concern the choice of the
relevant therapeutic gene, of appropriate pro-
moter and regulatory sequences and of an
effective vector for delivering the transgene or
trangenes into target cells. Thus gene therapy is a
matter of genes, vectors, promoters, and regula-
tory elements. Promoter and vector features
determine transduction efficacy and specificity,
duration of transgene expression, and eventually
appearance of side effects.
Several approaches have been developed for
transferring genes to human tissues. Plasmidic
DNA can be transferred either directly, or
attached to cell specific ligands, or embedded in
lipidic formulations (liposomes).3 On the other
hand the transgene(s) can be incorporated into
defective viral particles to facilitate the entry into
the cells. Viral vectors are, in fact, the most
efficient vehicles for gene transfer. Different
viruses have served to construct gene therapy
vectors, including adenoviruses,7 retroviruses8
(including lentivirus), AAV,9 herpesvirus,10
baculovirus,11 SV40 virus,12 vacciniavirus,13 and
others. The list of viral vectors is still expanding
andmodifications of already existing systems will
increase the number of potential applications of
gene therapy.
Murine retroviruses are single stranded RNA
viruses, which after interaction with a retrovirus
receptor can integrate in the genome of a dividing
cell. Cells that do not proliferate actively under
physiological conditions, such as hepatocytes, are
difficult to transduce with retroviral vectors. Fur-
thermore, transduction efficacy is limited by the
low titre of virus obtained with the production
procedures currently used.8 The recent develop-
ment of human lentiviral (human immuno-
deficiency virus) based vectors offers promising
perspectives for gene transfer into non-dividing
cells
Adenoviruses are double stranded DNA viruses
and serotypes 2 and 514 have been used exten-
sively for gene therapy of cancer. Adenoviral vec-
tors have a natural tropism for the liver, especially
in rodents, do not integrate into genomic DNA,
can infect very efficiently non-dividing cells and
are easily produced at high titres.15 Transgenes
carried by adenoviral vectors are expressed
transiently because of the host’s immune re-
sponse against viral proteins and the lack of DNA
integration into the host’s genome.6 Recently, the
so called large capacity or “gutless” adenovirus,
lacking all the viral sequences except the packag-
ing signals, have been shown to permit prolonged
transgene expression.17
AAV are non-pathogenic human parvoviruses
that, after deletion of all viral genes except ITR,
have been used successfully as gene therapy vec-
tors. AAV vectors do not induce significant
immune response and are able to transduce
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dividing and non-dividing cells. Because they can become
integrated into the host’s genome these vectors permit long
term transgene expression.18 After systemic injection AAV
demonstrate significant liver tropism.19 It has been shown that
AAV mediated gene transfer of Factor IX to mouse liver
induces persistent, curative levels of active factor IX.20 AAV
based vectors, as indicated for gutless adenoviruses, have con-
siderable potential in the treatment of central nervous system
disorders21 and also in diseases affecting muscle,22 a cell type
that is readily transduced by this type of viral agents.
Herpes simplex virus (HSV) is a promising vector for gene
transfer especially to the nervous system because of its
characteristic neurotropism.23 Additionally HSV transduces
effectively murine liver tissue in vivo.24
GENE THERAPY OF HEPATIC AND DIGESTIVE
TUMOURS
Primary liver cancer and tumours of the pancreas and GI tract
are very common neoplasms that frequently represent a
medical challenge because of the lack of curative treatment
when the progression of the disease precludes surgical resec-
tion. Transfer of therapeutic genes to the tumour mass or to
the peritumoral tissue provides a promising new approach to
treat these processes. Intense efforts are being made at both
preclinical and clinical level to develop gene therapy strategies
for advanced digestive tumours. Different gene therapy based
approaches have been tested to treat cancer including replace-
ment of functional tumour suppressor genes, inhibition of
oncogenes, transference to tumoral cells of genes conferring
sensitisation to a specific prodrug (“suicide genes”), stimula-
tion of antitumoral immunity, and inhibition of the formation
of tumoral neovessels (fig 1).
Data from pilot clinical studies have shown a limited
efficacy of treatments based on suicide genes and tumour
supressor genes. Considerable hope is placed in the antitu-
moral effect of cytokines, such as interleukin (IL) 12, endowed
with potent antitumoral activity. IL12 acts by inducing a TH1
type of response, activating NK cells and cytotoxic T
lymphocytes, inhibiting tumoral neoangiogenesis, and in-
creasing the expression of adhesion molecules on endothelial
cells thus facilitating the traffic of lymphocytes to the
tumour.25 This cytokine, however, is toxic when administered
systemically as a recombinant protein.26 The rational for IL12
gene therapy is to allow local production of the cytokine at the
tumour site thus achieving high intratumour or peritumoral
levels but low serum concentration, a scenario that might
result in maximal antitumoral effect with minimal systemic
toxicity.
In an orthotopic model of primary liver cancer in Buffalo
rats we have shown that intratumoral administration of
recombinant adenovirus encoding IL12 (Ad.IL12) caused
complete tumour eradication in most of animals and
increased long term survival. Interestingly when two tumours
were separately implanted in the same liver, treatment of only
one of them resulted in regression of both.27 This effect has
been attributed to the fact that a proportion of the
adenoviruses injected into a neoplastic nodule escapes to the
general circulation and, because of their strong liver tropism,
will infect the whole liver. The IL12 produced by the tumour
and by hepatocytes surrounding the neoplastic nodules
strongly activates NK cells, induces specific anti-tumour
immunity, stimulates expression of adhesion molecules in the
tumour vessels and displays a powerful anti-angiogenic effect
with resulting tumour regression.27 Ad.IL12 given by intra-
hepatic arterial route was also shown to be efficient in the
treatment of a very aggressive model of multifocal hepatocel-
lular carcinoma in rats (induced by DENA) causing a signifi-
cant reduction of tumour burden and prolongation of
survival.27 Ad.IL12 was also found to induce potent anti-
tumour effects in animal models of colorectal cancer
metastatic to the liver either by intratumoral injection or by
systemic administration resulting in peritumoral gene
transfer.28
Although IL12 based gene therapy demonstrates an intense
anti-tumour effect it may also cause toxicity because of the
ability of IL12 to induce interferon gamma production. To
increase the anti-neoplastic activity of IL12 while reducing the
risk of toxicity we have tested the therapeutic effect of inject-
ing intratumorally a suboptimal dose of Ad.IL12 when given
in combination with an adenovirus expressing the chemokine
IP-10. The rationale was to attract immunoeffector cells to the
neoplasm through IP-10 production and to activate the
attracted lymphocytes with IL12.We found that this combined
treatment allows reducing the dose of Ad.IL12 without losing
anti-tumour efficacy but with less risk of toxicity.29
It is known that dendritic cells are the most efficient
antigen presenting cells. As activation of dendritic cells is
critical for the induction of anti-tumour immunity, another
possible way to take advantage of the therapeutic effect of
IL12 is to infect dendritic cells with Ad.IL12 ex vivo and to
inject these engineered dendritic cells into the tumour. In ani-
mal models of colon cancer this strategy has proved to be
extremely potent at eliminating neoplastic lesions and at elic-
iting anti-tumoral immunity.30
Stimulation of dendritic cells is widely dependent on
activation by costimulatory molecules like B7 and CD40
ligand.We observed that adenovirus mediated gene transfer of
CD40 ligand completely abolished the tumourigenicity of ex
vivo infected rat hepatocellular carcinoma cells and that intra-
tumoral injection of this adenovirus into established intrahe-
patic tumour nodules in rats resulted in tumour regression
and prolongation of survival. Treatment of rat liver cancer with
an adenovirus coding for CD40 ligand induced protective
anti-tumour immunity and was devoid of significant
toxicity.31
Although many of these strategies have proved very
efficient antitumoral treatments in animals, there is still little
information concerning the safety and efficacy of these thera-
peutic modalities in the different forms of malignancies in
humans. Efficacy and toxicity depends greatly on the
therapeutic gene, the type of the vector, the dose and route of
administration, and the type of tumour being treated. Despite
the fact that the total number of phase I/II clinical studies
already done and presently conducted is substantial, the
diversity of vectors, doses and routes of administration, and
the variety of therapeutic genes used to treat different
tumours make very premature the analysis of the potential of
cancer gene therapy in humans. Moreover because gene
therapy is still an investigational procedure many of the trials
have been performed in patients with advanced tumours who
have progressed despite chemotherapy (fig 2). Thus the infor-
mation of the efficacy of gene therapy in early cancer in
patients with intact immune system is very limited.
Figure 1 Different gene therapy strategies to treat cancer.
Tumour cell
Gene therapy of cancer
Reversing the
malignant phenotype
Antiangiogenic
intervention
Molecular
chemotherapy
Genetic
immunotherapy
ii50 Prieto, Herraiz, Sangro, et al
www.gutjnl.com
 group.bmj.com on April 25, 2012 - Published by gut.bmj.comDownloaded from 
Gene therapy of chronic viral hepatitis
Gene therapy is a promising procedure to treat chronic viral
infections and to modulate chronic inflammatory processes.
Chronic viral hepatitis C or B affect several hundred million
people worldwide and more than 70% of patients with chronic
viral hepatitis are resistant to the standard antiviral therapy
with interferon (IFN) alfa. This is an important medical prob-
lem as unresolved chronic viral hepatitis may evolve to liver
cirrhosis and eventually to hepatocellular carcinoma. Recent
progress has taken place with the introduction of lamivudin in
the treatment of chronic hepatitis B,32 with the use of combi-
nation therapy of IFN alfa plus ribavirin in chronic hepatitis
C33 34 and with the development of pegylated IFN alfa, which
generates sustained levels of IFN alfa in the blood after one
weekly injection.35 However, despite these improvements a
high percentage of patients with chronic viral hepatitis are still
resistant to existing antiviral therapies. Gene therapy opens
new avenues to treat these patients. Thus the transfer of the
IFN alfa gene to liver cells would convert these cells into an
IFN factory permitting high and sustained intrahepatic levels
of IFN with lower serum concentration of the cytokine thus
increasing the therapeutic index of this substance. To achieve
this goal it would be necessary to use hepatotropic long term
expression vectors encoding IFN alfa gene under the control of
regulatable promoters responding to drugs such doxicycline or
mefipristone. This therapeutic modality will make it possible
to control the intrahepatic production of IFN alfa by adjusting
the oral dose of the inducer drug, thus permitting the increase
of the synthesis of IFN or to stop its production according to
the evolution of the viraemia. As IFN has demonstrated
significant antifibrogenic and anti-tumoral activities, IFN alfa
gene therapy of chronic viral hepatitis might also prove of
efficacy to prevent fibrosis progression36 and the development
of hepatocellular carcinoma.37
The fact that the transfer of IFN alfa gene to the liver
induces strong antiviral effects has recently been shown by
using adenoviral vectors in the prevention of viral hepatitis in
a mouse model.38 Proof of the concept that IFN alfa gene
therapy might be an efficient and tolerable procedure to treat
chronic viral hepatitis will stem from studies using appropri-
ate long term expression vectors in animals chronically
infected with hepatitis viruses such as woodchucks with
chronic woodchuck hepatitis virus (WHV) infection.
Another therapeutic approach to treat viral hepatitis is the
use of antisense DNA/RNA39 40 or ribozymes41 to inhibit the
expression of viral genes. By conveying these molecules in
long term expression vectors capable of integration into the
host genome, a certain proportion of hepatocytes (and their
progeny) would be rendered resistant to viral infection. As
these cells might enjoy a biological advantage over infected
cells, it is hoped that the replacement of dead hepatocytes
might take place preferentially by the transduced cells, which
finally might repopulate the entire liver. These assumptions
should be tested in the future in experimental animal models.
Antiviral immunity can be stimulated by the use of genetic
vaccination that is an efficient system to induce prophylactic
or therapeutic immune responses. Injection of naked DNA or
vectors containing viral genes, which can be combined with
genes of immunostimulatory cytokines, has been shown to
afford antiviral protection. In a recent work we found that
gene gun bombardment of woodchucks with DNA containing
the nucleocapsid of WHV together with another plasmid cod-
ing for woodchuck IL12, resulted in the generation of a strong
TH1 type immune response that efficiently protected the ani-
mals against viral inoculation.42 This protection was not
observed when animals were vaccinated with DNA encoding
WHV nucleocapsid alone. Similarly we found that combined
administration of an adenovirus containing the core and E1
sequences from HCV (AdCE1) and another one containing the
genes of IL12 (Ad.IL12) generated a TH1 immune response
that was more intense than that obtained after the injection of
Ad.CE1 alone.43 Therefore, genetic vaccination offers the
possibility of combining the genes coding for the antigen with
genes encoding immunomodulatory cytokines thus enabling
to steer the immune response in the desired direction.
Gene transfer to GI tract and gene therapy of
inflammatory bowel disease
There are a number of disorders of the intestinal epithelium
that could be amenable to gene therapy. In addition, the intes-
tine could be used as an alternative site for the production of
proteins that need to be secreted to the blood for the correction
of disorders such as haemophilia.
The intestinal tract has many features that make it an
attractive target for therapeutic gene transfer: (a) easy acces-
sibility via the intestinal lumen; (b) large surface area of the
epithelium; (c) the possibility of in situ gene transfer by
endoscopy; (d) known location of stem cells within the intes-
tinal crypt, (e) intestinal cells can secrete foreign protein into
the circulation.
Methods of gene transfer to the gastrointestinal tract
Several methods of gene transfer to the GI tract have been
used. Most of the techniques target the epithelium but a sub-
mucosal approach may transduce cells of the muscularis
mucosae.44
It has been demonstrated in vivo gene transfer to various
locations of the gastrointestinal tract such as oesophagus,
stomach, and colon using cationic liposomes.45 46 Gene transfer
was achieved by luminal instillation using catheter infusion. A
high efficiency of transfection was observed in colonic epithe-
lium, with near 100% of epithelial cells expressing the
transgene. Transgene expression was transient and did not
persist beyond four days, a finding that is consistent with the
normal turnover time of gut epithelium. However, repeated
treatments can achieve maintained expression of the foreign
gene. Intramural injection of liposomes through a needle is
also possible and in this case the transgene is expressed pref-
erentially in fibroblasts.44
Genes can be transferred into the intestinal epithelium
using retroviral vectors introduced intraluminally.47 Given the
continual proliferation of this tissue, these vectors would be an
appropriate choice because of their ability to transduce divid-
ing cells. However, transduction efficiency is comparatively
low in the intestine of rat and mice and thus retroviral vectors
would not satisfy the requirements of gene therapy in
humans.
Adenoviral vectors have been shown to transduce intestinal
cells in vivo when administered through an oral-duodenal
Figure 2 Echo guided intratumoral injection of an adenoviral
vector encoding IL12 in a patient with non-resectable hepatocellular
carcinoma.
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tube.48 The considerable transduction efficiency of adenovi-
ruses most probably reflects the fact that the intestine is a
normal site of infection for this virus. Transfer of genetic
material with adenoviruses is more successful in the small
intestine as compared with the colon. Interestingly, single or
repeated challenge with adenoviral vector did not cause
increased host immune responses to this virus, suggesting
that this type of vectors could be a good candidate for gene
therapy of intestinal diseases.48 Also it has been demonstrated
that adenovirus mediated gene transfer to intestinal epithelial
cells can effectively deliver proteins to the circulation indicat-
ing that intestinal cells have the potential to be used as
heterotopic sites for production of peptidic hormones,
cytokines, and proteins that should function in plasma.49
As the epithelium turns over rapidly (two to four days), the
ideal targets for a stable gene transfer would be the intestinal
stem cells. Permanent gene transfer is conceivable if the gene
of interest can be integrated into intestinal stem cells. Acces-
sibility of these cells to vectors delivered into the intestinal
lumen is limited by their deep location and by the mucus that
lines the epithelium. In vitro experiments have shown that
intestinal mucus can be solubilised by a variety of agents
including proteases, detergents, and sulfhydryl compounds.50
In vivo pilocarpine pretreatment followed by a phosphate
buffered saline flush may effectively reduce the mucus barrier
in the crypts for a period of time facilitating gene transfer by
either adenoviruses or other vectors.51
Another promising vector for gene transfer to the gut is the
one based on AAV. It has been demonstrated that an orally
administered AAV vector leads to persistent expression of a
β-galactosidase transgene in both gut epithelial and lamina
propria cells, and that this approach results in long term phe-
notypic recovery in an animal model of lactose intolerance.52
AAV has several features that make it particularly useful for
gene therapy:wild type AAV is non-pathogenic in humans, the
vector lacks all viral genes minimising any possible recombi-
nation and induces only very mild immunological responses.
Another singularity that makes AAV especially suitable as an
orally delivered vector is its hardiness being very resistant to
changes in pH and temperature and to solvents. The persistent
and stable gene expression for almost six months is also
another interesting feature. As enterocyte turnover is three to
five days, this prolonged expression indicates that progenitor
cells lying within the crypts can be transduced by AAV vectors.
All these features make AAV an attractive vector for GI gene
transfer with potential application for vaccination purposes
and for maintained protein replacement, particularly when
the release of the protein into the portal circulation is a desired
goal.
Gene therapy for inflammatory bowel disease
Crohn’s disease and ulcerative colitis are chronic inflamma-
tory bowel diseases of unknown aetiology,which show a rising
incidence in Western countries. Although important advances
have been made in the treatment of these conditions, the
process is ill controlled in a substantial number of patients
with severe disease. The chronic inflammatory reaction seems
to result from a pronounced activation of local mucosal type I
proinflammatory immune response. IL10 plays a crucial part
in the balance of the mucosal immune system, promoting
physiological activation, and preventing the pathological
inflammation that characterises such diseases.53 Evidence
from murine models suggests that IL10 induces tolerance to
luminal antigen by inhibiting both proinflammatory cytokine
release and antigen presentation, and also by the generation of
antigen specific regulatory T cell clones.54 Gene targeted IL10
deficient mice develop transmural inflammation of the small
and large bowel, reminiscent of Crohn’s disease. This type of
inflammation is aggravated by the presence of bacteria within
the gut lumen, and can be prevented by administration of
IL10.55 These data lead to the consideration of IL10 as a cyto-
kine with potential application in inflammatory bowel
diseases. However, side effects have limited the use of
systemically administered recombinant human IL10
(rHuIL10) in these conditions. Gene transfer of IL10 to the
diseased tissues is a alternative therapeutic approach for
inflammatory bowel diseases as this procedure might permit
the generation of high local levels of the cytokine and concen-
trate its immunoregulatory activity in the bowel while avoid-
ing systemic side effects.56 At present there is an ongoing
clinical trial using liposomes with IL10 DNA for local delivery
to patients with inflammatory whose results are awaited with
interest.57
GI directed gene therapy of inflammatory bowel disease can
also use molecular constructs directed to inhibit expression of
proinflammatory cytokines such as IL18 that has been shown
to be highly upregulated in Crohn’s disease. Recent work has
shown that an adenovirus expressing IL18 antisense RNA was
able to suppress IL18 by intestinal cells and to reduce IFN
gamma production and the activity of experimental colitis in
a murine model.58
CLINICAL IMPLEMENTATION OF GENE THERAPY
As gene therapy is in its infancy, this procedure remains an
experimental therapeutic modality, which is reserved for
clinical trials of serious, frequently deadly, human diseases
lacking effective treatment. A great proportion of clinical
studies being presently conducted concern patients with
advanced untreatable tumours. These pilot studies are phase
I/II trials using escalating doses of the vector to determine
toxicity in the first place and secondly efficacy.Data from these
trials will be essential for a real understanding of the potential
of gene therapy in humans because although there is a wealth
of data in rodents regarding the ability of gene therapy vectors
to transduce different organs and to combat many types of
malignancies, it seems possible, and even probable, that the
tropism of gene therapy vectors is not the same for human and
rodent tissues. Moreover, it is plausible that the antitumoral
effect or the toxicity of a given vector with a specific therapeu-
tic gene is different in rodents and in humans. Thus progress
in gene therapy is basically dependent on data obtained in
clinical trials.
The success or failure of a defined viral vector with a specific
transgene (or transgenes) to control the growth of a particu-
lar tumour depends not only of the intrinsic biological activity
of the transferred therapeutic gene but also, and very
importantly, from the ability of the viral vector to infect the
target tissue. To consider a particular case, although gene
transfer of IL12 could be a very attractive procedure to treat
metastatic colon cancer to the liver, this treatment will not
succeed if the vector conveying the therapeutic gene fails to
infect the tumour or the peritumoral tissue in humans. It is
clear therefore that the use of appropriate molecular imaging
techniques to trace the expression of the transgene are critical
to analyse what are the factors determining the efficacy or lack
of efficacy of a given vector to fight cancer. In other words,
clinical data from pilot clinical trials of cancer gene therapy
will not give all the necessary information without the
knowledge of the localisation of transgene expression
provided by in vivo imaging methods such as positon emission
tomography59 60 (fig 3). This procedure will also be important
to establish comparisons of different vectors and routes of
vector administration with respect their ability to transduce a
given human neoplasm. At the birth of cancer gene therapy
this information is essential for the rational progress of the
field.
THE FUTURE
Gene therapy has emerged as a powerful and very plastic tool
to govern biological functions of the tissues with a therapeu-
tic aim. Animal models of human diseases and pilot clinical
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studies clearly show that there is a future for genes to be used
as curative drugs. Gene therapy is at its beginning and much
remains to be done before this procedure becomes of general-
ised use. New vectors with improved transduction efficiency,
transgene capacity, toxicity profile, and duration of expression
should be designed. Systems to control gene expression
should be improved. Efficient therapeutic genes or combina-
tion of genes to treat those entities amenable to gene therapy
should be identified. Different routes and procedures for vec-
tor administration should be tested. A regulatory policy
aiming at patient and environment safety on one side and
functionality of gene therapy programmes on the other should
be implemented and harmonised among different countries.
Innovative methods for large scale industrial production of
gene therapy vectors to permit cheap dispensation of these
new drugs should be developed. Finally, creative methods for
the in vivo tracing of transgene expression in humans should
be introduced to monitor vector distribution and transduction
efficiency. In conclusion, the field of gene therapy is new but
wide open. No doubt it will represent a historical step in the
advancement of clinical medicine.
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